Back
Viridian Therapeutics, Inc. 10K Form
Sell
47
VRDN
Viridian Therapeutics, Inc.
Last Price:
$28.33
Seasonality Move:
-16.34%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive VRDN News And Ratings
See the #1 stock for the next 7 days that we like better than VRDN
VRDN Financial Statistics
Sales & Book Value
| Annual Sales: | $70.8M |
|---|---|
| Cash Flow: | $-24.5M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $5.80 |
| Price / Book: | 5 |
Profitability
| EPS (TTM): | -3.80650 |
|---|---|
| Net Income (TTM): | $-324.2M |
| Gross Margin: | $69.7M |
| Return on Equity: | -53.74% |
| Return on Assets: | -46.82% |
Viridian Therapeutics, Inc. Earnings Forecast
Key Viridian Therapeutics, Inc. Financial Ratios
-
The Gross Profit Margin over the past 14 years for VRDN is 98.36%.
-
The Selling, General & Administrative Expenses for VRDN have been equal to 134.53% of Gross Profit Margin.
-
The Research & Development expenses have been 477.73% of Revenue.
-
The Net Earning history of VRDN is -397.93% of Total Revenues.
-
Per Share Earnings over the last 14 years have been positive in 7 years.
Viridian Therapeutics, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | VRDN |
| Website: | viridiantherapeutics.com |
Debt
| Debt-to-Equity Ratio: | 0.07 |
|---|---|
| Current Ratio: | 12.65 |
| Quick Ratio: | 12.37 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
VRDN Technical Analysis vs Fundamental Analysis
Sell
47
Viridian Therapeutics, Inc. (VRDN)
is a Sell
Is Viridian Therapeutics, Inc. a Buy or a Sell?
-
Viridian Therapeutics, Inc. stock is rated a SellThe current Viridian Therapeutics, Inc. [VRDN] share price is $28.89. The Score for VRDN is 47, which is 6% below its historic median score of 50, and infers higher risk than normal.